Importantly, blocking the CCL3 signal with BX471 (an antagonist of CCR1) effectively restored the effect of CCL3 on the downregulation of the transcription factor GATA1 in CD34+ cells in the myeloma microenvironment (Fig. 7C). Here, CD34 is linked to plasma cell myeloma.